ANXA2 and leukemia: The percentage of human cells in mouse blood increased rapidly in mice treated with control IgG (doubling time = 4.66 ± 0.29 days), while the mice treated with anti-ANX2 antibody showed a slower progression (doubling time = 2.92 ± 0.03 days) (Fig 5E), suggesting that anti-ANX2 antibody reduced NTPL-20 engraftment and leukemia progression.